Cargando…

Targeting the VEGF Pathway in Osteosarcoma

Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Tarek, Watson, Sarah, Samra, Bachar, Rassy, Elie, Le Cesne, Axel, Italiano, Antoine, Mir, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157846/
https://www.ncbi.nlm.nih.gov/pubmed/34069999
http://dx.doi.org/10.3390/cells10051240
_version_ 1783699769257885696
author Assi, Tarek
Watson, Sarah
Samra, Bachar
Rassy, Elie
Le Cesne, Axel
Italiano, Antoine
Mir, Olivier
author_facet Assi, Tarek
Watson, Sarah
Samra, Bachar
Rassy, Elie
Le Cesne, Axel
Italiano, Antoine
Mir, Olivier
author_sort Assi, Tarek
collection PubMed
description Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the pathophysiology of this subtype of sarcoma has led to the identification of new targeted agents with significant activity. In fact, increased angiogenesis plays a major role in the tumor growth and survival of osteosarcoma patients. Several targeted agents have demonstrated a significant anti-tumor activity including multi-kinase inhibitors. In this review, we will discuss the pathophysiology, rationale, and role of targeting angiogenesis via the VEGF pathway in patients with osteosarcoma with emphasis on the published clinical trials and future directions.
format Online
Article
Text
id pubmed-8157846
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81578462021-05-28 Targeting the VEGF Pathway in Osteosarcoma Assi, Tarek Watson, Sarah Samra, Bachar Rassy, Elie Le Cesne, Axel Italiano, Antoine Mir, Olivier Cells Review Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the pathophysiology of this subtype of sarcoma has led to the identification of new targeted agents with significant activity. In fact, increased angiogenesis plays a major role in the tumor growth and survival of osteosarcoma patients. Several targeted agents have demonstrated a significant anti-tumor activity including multi-kinase inhibitors. In this review, we will discuss the pathophysiology, rationale, and role of targeting angiogenesis via the VEGF pathway in patients with osteosarcoma with emphasis on the published clinical trials and future directions. MDPI 2021-05-18 /pmc/articles/PMC8157846/ /pubmed/34069999 http://dx.doi.org/10.3390/cells10051240 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Assi, Tarek
Watson, Sarah
Samra, Bachar
Rassy, Elie
Le Cesne, Axel
Italiano, Antoine
Mir, Olivier
Targeting the VEGF Pathway in Osteosarcoma
title Targeting the VEGF Pathway in Osteosarcoma
title_full Targeting the VEGF Pathway in Osteosarcoma
title_fullStr Targeting the VEGF Pathway in Osteosarcoma
title_full_unstemmed Targeting the VEGF Pathway in Osteosarcoma
title_short Targeting the VEGF Pathway in Osteosarcoma
title_sort targeting the vegf pathway in osteosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157846/
https://www.ncbi.nlm.nih.gov/pubmed/34069999
http://dx.doi.org/10.3390/cells10051240
work_keys_str_mv AT assitarek targetingthevegfpathwayinosteosarcoma
AT watsonsarah targetingthevegfpathwayinosteosarcoma
AT samrabachar targetingthevegfpathwayinosteosarcoma
AT rassyelie targetingthevegfpathwayinosteosarcoma
AT lecesneaxel targetingthevegfpathwayinosteosarcoma
AT italianoantoine targetingthevegfpathwayinosteosarcoma
AT mirolivier targetingthevegfpathwayinosteosarcoma